欢迎来到天天文库
浏览记录
ID:34582014
大小:2.17 MB
页数:51页
时间:2019-03-08
《左卡尼汀注射液对扩张型心肌病的辅助治疗作用及体内卡尼汀群的代谢研究》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、摘要目的:研究左卡尼汀注射液对扩张型心肌病患者的辅助治疗作用,揭示患者血浆卡尼汀群浓度变化与其辅助治疗DCM疗效的相关性。方法:按1995年中华心血管病学会提出的DCM诊断标准筛选100例扩张型心肌病(DCM)患者随机分成治疗组和对照组(各50例),对照组患者接受呋塞米片、13受体阻滞剂、血管紧张素转换酶抑制剂、单硝酸异山梨酯注射液及地高辛片的常规治疗,治疗组在常规治疗的基础上加用左卡尼汀注射液2.0g加入0.9%氯化钠20ml稀释后静推,一天2次,疗程为14天。采用西门子ACUSONX300彩色多普勒超声仪检测治疗前、后两组患者的每博输出量(Sv)、心排血量(Co)、射血分数
2、(LVEF),复制柱前衍生高效液相色谱法(highperformanceliquidchromatography,HPLC)检测治疗前后扩张型心肌病病人体内左卡尼汀(L-camitine,LC)、乙酰左卡尼汀(acetyl.L-camitine,ALC)、丙酰左卡尼汀(propionyl.1.carnitine,PLC)含量,对治疗前后所有数据应用统计软件SPSS20.0进行统计分析。结果:(1)治疗前两组患者在性别、年龄、心功能等方面差异无统计学意义(P>O.05)(2)治疗14天后,对照组的左室射血分数(51.9±4.3)%、每博输出量(51.73±3.81)ml/beat
3、、心排血量(5.4±0.5)L/min较治疗前均有显著提高(P<0.05)(3)治疗组给药14天后的左室射血分数(LVEF)(59.5±5.2)%、心排血量(co)(5.9±0.5)L/min、每搏出量(SV)(62.30-1-4.80)ml/beat较治疗前也有显著提高且较对照组同期均有明显增加(P4、64±6.71)1.tmol·L-1(21.40±3.11)kttool·L1(9.72±2.05)latool·L.1,较治疗前均有所提高,且明显高于对照组同期(P5、mentofdilatedcardiomyopathyandinvestigatetherelationshipbetweenthechangesofplasmacamitineconcentrationandtherapeuticeffect.MethodsAcordingtoDCMdiagnosticcriteriaproposedbytheInstituteofcardiovasculardiseaseinChinain1995,100casesofdilatedcardiomyopathy(DCM)patientswerescreened.Theywererandomi6、zedintotreatmentandcontrolgroups(50each),thecontrolgroupreceivedconvertionaltreatmentincludingoraladministrationoffurosemidetablets,beta-blockers,angiotensinconvertingenzymeinhibitors,digoxinandintravenousinjectionofIsosorbideMononitrate,onthebasisofconertionaltreatmentthetreatmentgroupwerea7、dditionallyadministeredL-carnitineinjection(2.09bid)for14days.Todetectthesystolicvolume(SV),cardiacoutput(Co)andleftventricularejectionfraction(LVEF)ofthetowgroupsbeforeandafterthetreatmentbySiemensACUSONX300colorDoppler,andtodetecttheconcentration
4、64±6.71)1.tmol·L-1(21.40±3.11)kttool·L1(9.72±2.05)latool·L.1,较治疗前均有所提高,且明显高于对照组同期(P5、mentofdilatedcardiomyopathyandinvestigatetherelationshipbetweenthechangesofplasmacamitineconcentrationandtherapeuticeffect.MethodsAcordingtoDCMdiagnosticcriteriaproposedbytheInstituteofcardiovasculardiseaseinChinain1995,100casesofdilatedcardiomyopathy(DCM)patientswerescreened.Theywererandomi6、zedintotreatmentandcontrolgroups(50each),thecontrolgroupreceivedconvertionaltreatmentincludingoraladministrationoffurosemidetablets,beta-blockers,angiotensinconvertingenzymeinhibitors,digoxinandintravenousinjectionofIsosorbideMononitrate,onthebasisofconertionaltreatmentthetreatmentgroupwerea7、dditionallyadministeredL-carnitineinjection(2.09bid)for14days.Todetectthesystolicvolume(SV),cardiacoutput(Co)andleftventricularejectionfraction(LVEF)ofthetowgroupsbeforeandafterthetreatmentbySiemensACUSONX300colorDoppler,andtodetecttheconcentration
5、mentofdilatedcardiomyopathyandinvestigatetherelationshipbetweenthechangesofplasmacamitineconcentrationandtherapeuticeffect.MethodsAcordingtoDCMdiagnosticcriteriaproposedbytheInstituteofcardiovasculardiseaseinChinain1995,100casesofdilatedcardiomyopathy(DCM)patientswerescreened.Theywererandomi
6、zedintotreatmentandcontrolgroups(50each),thecontrolgroupreceivedconvertionaltreatmentincludingoraladministrationoffurosemidetablets,beta-blockers,angiotensinconvertingenzymeinhibitors,digoxinandintravenousinjectionofIsosorbideMononitrate,onthebasisofconertionaltreatmentthetreatmentgroupwerea
7、dditionallyadministeredL-carnitineinjection(2.09bid)for14days.Todetectthesystolicvolume(SV),cardiacoutput(Co)andleftventricularejectionfraction(LVEF)ofthetowgroupsbeforeandafterthetreatmentbySiemensACUSONX300colorDoppler,andtodetecttheconcentration
此文档下载收益归作者所有